[1]Narain JP, Lo YR. Epidemiology of HIV-TB in Asia. Indian J Med Res, 2004, 120(4): 277-289.[2]Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing counties: epidemiology and strategies for prevention. Tuber Lung Dis, 1992, 73(6): 311-321.[3]Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature, 1996, 384(6609): 529-534.[4]Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis(TB)on HIV-1 activity in dually infected patients. Clin Exp Immunol, 2001, 123(2): 233-238.[5]中国全球基金结核病项目办公室. 第五轮中国全球基金结核病项目(一期)TB/HIV双重感染防治实施方案. 北京:中国全球基金结核病项目办公室,2006:81.[6]谢惠安,阳国太,林善梓,等. 现代结核病学. 北京:人民卫生出版社,1999:176.[7]Gao L, Zhou F, Li X, et al. HIV/TB co-infection in mainland China: a meta-analysis. PLoS One, 2010, 5(5): e10736.[8]潘建敏,陈慧娟,李杨,等. 贵州省结核病/艾滋病双重感染筛查情况分析.中国防痨杂志,2010, 32(12): 788-791.[9]林桂新,段润宁,刘明团,等. 结核病人感染人类免疫缺陷病毒(HIV)监测结果分析. 中国预防医学杂志,2006, 7(5): 446-447.[10]刘飞鹰,王喜文. 61例HIV感染者与580例结核病人双重感染调查. 中国热带医学,2007, 7(7): 1109-1110.[11]王宇,李芳,郭肖岩,等.山东省全球基金TB/HIV双重感染防治项目筛查分析. 中国防痨杂志,2010, 32(12): 815-817.[12]崔为国,王林,王哲,等. HIV/AIDS患者结核菌素反应及与CD4细胞关系.中国公共卫生,2005, 21(6): 677-678.[13]Cohen T, Lipsitch M, Walensky RP, et al. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A, 2006, 103(18): 7042-7047.[14]彭国平,詹发先. 湖北省AIDS流行态势分析. 中国艾滋病性病,2004,10(4): 263-264.[15]Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 2001, 26(4): 326-331.[16]刘凤仁. HIV/AIDS人群中肺结核患者的抗结核治疗效果研究. 武汉:华中科技大学,2008.[17]Lawn SD, Wood R, De Cock KM, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis, 2010, 10(7): 489-498.[18]Mosimaneotsile B, Mathoma A, Chengeta B, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004—2006. J Acquir Immune Defic Syndr,2010, 54(1): 71-77.[19]Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, 2007, 21(11): 1441-1448.[20]赵丁源,叶建军,熊昌富,等. INH预防性治疗PPD试验阳性的HIV/AIDS患者的效果分析. 中国防痨杂志,2010, 32(11): 772-773.[21]殷继国,何卫华,练祖银,等. HIV/AIDS患者结核感染预防性治疗效果评价研究. 中国防痨杂志,2010, 32(12):791-794.[22]Waaler HT. Tuberculosis and poverty. Int J Tuberc Lung Dis,2002,6(9): 745-746.[23]Njozing NB, Miguel SS, Tih PM, et al. Assessing the accessibility of HIV care packages among tuberculosis patients in the Northwest Region, Cameroon. BMC Public Health, 2010,10: 129. |